UK markets closed

IMV Inc. (IMV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.3800-0.0600 (-1.74%)
At close: 4:00PM EDT

IMV Inc.

130 Eileen Stubbs Avenue
Suite 19
Dartmouth, NS B3B 2C4
Canada
902 492 1819
http://imv-inc.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees62

Key executives

NameTitlePayExercisedYear born
Mr. Frederic Ors M.B.A., B.Sc., M.A.CEO & DirectorN/AN/A1974
Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICDChief Financial OfficerN/AN/A1965
Ms. Joanne SchindlerChief Medical OfficerN/AN/AN/A
Mr. Marc Jasmin CPA, CMASr. Director of Investor RelationsN/AN/AN/A
Ms. Annie Tanguay B.Sc.Sr. VP of Quality & ComplianceN/AN/AN/A
Delphine DavanDirector of CommunicationsN/AN/AN/A
Dr. Marianne StanfordVP of R&DN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DPX drug development platform provides a patented delivery formulation that enables controlled and prolonged exposure of antigens to the immune system. The company develops DPX-Survivac, T cell activating immunotherapy that is in Phase II clinical trials for ovarian cancer and diffuse large B-cell lymphoma. It also develops DPX-RSV, a B cell epitope peptide vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7; and vaccine candidates for malaria and the Zika virus. IMV Inc. has collaboration and license agreements with Merck & Co., Inc., Dana-Farber Cancer Institute, Incyte Corporation, and Leidos Inc, as well as with Zoetis and The Wistar Institute; and a preclinical therapeutic research collaboration with Navidea Biopharmaceuticals, Inc. to explore the potential combinatory effect with their platform-based immunotherapies. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Corporate governance

IMV Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.